about
Antiviral drugs for viruses other than human immunodeficiency virusFactors associated with the response to interferon-based antiviral therapies for chronic hepatitis CA multiple-dose pharmacokinetics of polyethylene glycol recombinant human interleukin-6 (PEG-rhIL-6) in rats.Peginterferon alfa-2a is associated with elevations in alanine aminotransferase at the end of treatment in chronic hepatitis C patients with sustained virologic responseTherapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics.Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial.Interferons: Success in anti-viral immunotherapy.Peginterferon and ribavirin treatment for hepatitis C virus infectionEfficacy and Tolerability of Peginterferon α -2a and Peginterferon α -2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled TrialsA perspective on modelling hepatitis C virus infection.Management of patients with hepatitis C infection and renal disease.Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device.A phase 2 study of pegylated interferon α-2b (PEG-Intron(®)) in children with diffuse intrinsic pontine glioma.Chronic hepatitis C virus management: 2000-2005 update.Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency.Improving anti-hepatitis C virus therapy.PharmGKB summary: peginterferon-α pathway.Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C.Nanomedicines in the treatment of patients with hepatitis C co-infected with HIV--focus on pegylated interferon-alpha.SASLT practice guidelines: management of hepatitis C virus infection.Interferon-Related Depression: A Primer on Mechanisms, Treatment, and Prevention of a Common Clinical Problem.Long-term pegylated interferon-alpha and its potential in the treatment of melanomaPharmacotherapy of chronic hepatitis C virus infection - the IDEAL trial: '2b or not 2b (= 2a), that is the question'.Interferon combination therapy for HIV/hepatitis C virus coinfection.Telaprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C.A comparative study of variants of pegylated interferon alpha in treatment of chronic HCV patients.Use of an integrated modelling and simulation approach to develop a simplified peginterferon alfa-2a dosing regimen for children with hepatitis CType of pegylated interferon matters: another milestone in the treatment of hepatitis C virus infectionEfficacy and safety of low-dose peginterferon alpha-2a plus ribavirin on chronic hepatitis C.Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?Pegylated interferon for treatment in hemodialysis patients with chronic hepatitis C.Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy.KASL clinical practice guidelines: management of hepatitis C.
P2860
Q24635330-D685AC72-3EF7-4B98-8B69-B25238D38D5BQ26825715-96160F62-3C7D-4AA6-930D-40DC171189A4Q33393458-A76288CE-C0F0-4FB9-B794-E514F829786EQ33769085-02D4466C-4E1A-4385-B33E-BCFF143D8ECDQ33999004-4012668C-D715-48E0-A702-4D58C7A76A51Q34158350-ABD746B1-2AD4-43AB-9329-244DC1CC947AQ34276038-82BDFA9E-5047-493E-973B-8EC3DB7EBCA2Q34521371-C91A2522-33CE-429C-9A03-A94D702B6904Q34714220-B6628735-3495-438C-AB0C-4340CD72AFD3Q34759489-BD7FFA0A-8572-4494-9F4C-278E9D6D26A3Q35127041-80147ECB-4516-4B04-9070-0C6D3FB69495Q35604803-93516D5F-5119-4329-B94D-1C6422037782Q35791274-772122ED-E547-4DF6-A905-0007941AC597Q36348376-0B6B7BA7-F548-45D6-B5D3-1F364E079A64Q36379874-4E6980BF-948C-482D-86FF-C604D1211273Q36569749-C8B86C12-386B-4010-A2F9-1571D304B0F7Q36590755-BA14B027-890A-44D6-B8B0-3F8B837D0F17Q36779201-0BEE1167-E828-4CEB-916A-3BC513D657CAQ36920320-2DD0B361-8E81-461C-BD70-B4AA7A65B95DQ37019765-DD23B2B7-ED1E-49D7-A0A3-834B379A7523Q37310556-61D8F075-19D2-4DDB-8A30-B0E80FA0FFF3Q37586916-7D1A7DCB-43EB-4CA1-A465-52B879FB1423Q37627878-5E3BE9DE-DA19-4AB0-8714-253EAC951975Q37931258-ADAEC59A-AB80-4434-ACCC-39C0A34A6554Q37939247-C339F467-0A01-4193-98A1-8719DEFC3F69Q38985556-449CF7E1-E48B-4648-A3B8-37D94B5CA2DBQ39220698-4F61E354-1D70-4DE5-B26D-F9CB385326A5Q40753560-473F7C47-7CD9-4619-946E-F72D8E049AD6Q42281901-17D1C616-51FD-4841-A791-E926CF70E254Q50557265-777C5D64-03AC-46BA-B234-33FE4A218719Q50576430-47B6ACA6-A406-4FC8-BFE6-7EF1F3107EB0Q50579191-F56E3274-FB06-4954-9D27-1C3D9A5F6885Q51836024-B93579D9-13FE-4921-82E5-10AFE8680622
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Pharmacokinetics of peginterferons.
@ast
Pharmacokinetics of peginterferons.
@en
type
label
Pharmacokinetics of peginterferons.
@ast
Pharmacokinetics of peginterferons.
@en
prefLabel
Pharmacokinetics of peginterferons.
@ast
Pharmacokinetics of peginterferons.
@en
P356
P1476
Pharmacokinetics of peginterferons.
@en
P2093
Christoph Welsch
Eva Herrmann
P356
10.1055/S-2003-41631
P478
23 Suppl 1
P577
2003-01-01T00:00:00Z